ANDA 218651, held by Zydus Lifesciences. Fluorescein Sodium.
As of Nov 16, 2026, ANDA 218651 (Fluorescein Sodium), held by Zydus Lifesciences, was first approved by FDA on Jun 1, 2026, with 0 approved supplements and 0 published complete response letters.
Fluorescein injection 10% (100 mg/mL) and 25% (250 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 2026 | Original application | Approved | None posted |
| Fluorescein SodiumEQ 500MG BASE/5ML (EQ 100MG BASE/ML) · injectable;intravenous | Fluorescein Sodium | Rx |
| Fluorescein SodiumEQ 500MG BASE/2ML (EQ 250MG BASE/ML) · injectable;intravenous | Fluorescein Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters